Recent Advances in Nanomedicine-Based Cancer Immunotherapy

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".

Deadline for manuscript submissions: 31 August 2024 | Viewed by 1331

Special Issue Editors

E-Mail Website
Guest Editor
Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore
Interests: T-cell immunology; non-Hodgkin lymphoma; immunotherapy; nanomedicine

E-Mail Website
Guest Editor
Department of Surgery, Yong Loo Lin School of Medicine, Level 8. IE Kent Ridge Road, Singapore 119228, Singapore
Interests: endocrine cancers; aberrant glycans
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, The University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA
Interests: stem cells; premalignancy; disease modeling; drug discovery; nanotechnology; lung cancer; immuno-oncology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

It is our pleasure to announce a call for submissions to this Special Issue of Cancers, "Recent Advances in Nanomedicine-Based Cancer Immunotherapy". Cancer is a leading cause of death worldwide. Nearly 10 million deaths related to cancer were recorded in 2020 by the World Health Organization. With substantial innovation in early diagnosis and effective treatment regimens, many cancers have a high chance of cure. Exciting advances over the past decade have led to immunotherapies that harness the powerful antitumor activity of the immune system to fight cancer. Immunotherapies have proven a miracle for several types of cancers, including melanoma, lymphoma, bladder cancer, stomach cancer, liver cancer, kidney cancer, head and neck cancers, breast cancer, small cell lung cancer, and non-small cell lung cancer. However, challenges remain. They do not work for all patients and are associated with long-term adverse effects, toxicities, drug resistance, and autoimmunity. In this context, recent advancements in nanotechnologies have greatly improved the effectiveness of cancer immunotherapies.

This Special Issue aims to provide a comprehensive overview of the principles, techniques, new advancements, and recent discoveries, from basic research to clinical translation, of applying nanotechnologies in the field of cancer immunotherapies.

In this Special Issue, original research articles, reviews, and commentaries that cover the relevant topics in this area are welcome. We also solicit work on completed and/or ongoing clinical trials utilizing nanotechnologies for enhancing the effectiveness of cancer therapeutics. Findings from studies employing advanced molecular nanotechnologies in nano-enabled therapeutics are also welcome. Topics include, but are not limited to, the following:

  • Combination immune checkpoint inhibitors with core–shell nanoparticles;
  • Functionalized or biomimetic nanoparticle design and engineering for immunotherapy;
  • Nanomedicine for immune-stimulatory molecules;
  • CRISPR-Cas nanoparticles in immunotherapy;
  • Nanotechnology delivery platform for immunotherapies or CAR T-cells;
  • Nanomedicine bispecific antibodies;
  • Nanomedicine oncolytic virotherapies;
  • Nanotechnologies overcoming resistance, side effects, or toxicities of immunotherapies;
  • Nanotechnologies for identifying new biomarkers of immunotherapies;
  • Pharmacokinetics of nanomedicine-based cancer immunotherapy.

We look forward to receiving your contributions.

Dr. Navin Kumar Verma
Dr. Rajeev Parameswaran
Dr. Manash Paul
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • cancer nano-therapy
  • nano-enabled therapeutic
  • immune checkpoint inhibitors
  • tumor immunosuppression
  • adoptive cell therapy
  • CAR T-cell therapy
  • tumor-infiltrating lymphocyte therapy
  • monoclonal antibody therapy for cancer
  • cancer vaccines
  • immune system modulators

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


16 pages, 4729 KiB  
Specific Tumor Localization of Immunogenic Lipid-Coated Mesoporous Silica Nanoparticles following Intraperitoneal Administration in a Mouse Model of Serous Epithelial Ovarian Cancer
by Achraf Noureddine, Benjamin Marwedel, Lien Tang, Lorel Y. Medina and Rita E. Serda
Cancers 2023, 15(18), 4626; - 19 Sep 2023
Cited by 1 | Viewed by 1031
Immunogenic lipid-coated mesoporous silica nanoparticles (ILM) present pathogen-associated molecular patterns (PAMPs) on the nanoparticle surface to engage pathogen-associated receptors on immune cells. The mesoporous core is capable of loading additional immunogens, antigens or drugs. In this study, the impact of lipid composition, surface [...] Read more.
Immunogenic lipid-coated mesoporous silica nanoparticles (ILM) present pathogen-associated molecular patterns (PAMPs) on the nanoparticle surface to engage pathogen-associated receptors on immune cells. The mesoporous core is capable of loading additional immunogens, antigens or drugs. In this study, the impact of lipid composition, surface potential and intercalation of lipophilic monophosphoryl lipid A (MPL-A) in the lipid coat on nanoparticle properties and cellular interactions is presented. Loading and retention of the model antigen ovalbumin into the mesoporous silica core were found to be similar for all nanoparticle formulations, with presentation of ova peptide (SIINFEKL) by major histocompatibility complex (MHC) evaluated to facilitate the selection of an anionic nanoparticle composition. ILM were able to induce lysosomal tubulation and streaming of lysosomes towards the cell surface in dendritic cells, leading to an enhanced surface presentation of MHC. Myeloid cells robustly internalized all ILM formulations; however, non-myeloid cells selectively internalized cationic ILM in vitro in the presence of 20% serum. Interestingly, ILM administration to the peritoneal cavity of mice with disseminated ovarian cancer resulted in selective accumulation of ILM in tumor-associated tissues (>80%), regardless of nanoparticle surface charge or the presence of MPL-A. Immunofluorescence analysis of the omental tumor showed that ILMs, regardless of surface charge, were localized within clusters of CD11b+ myeloid cells 24 h post administration. Selective uptake of ILMs by myeloid cells in vivo indicates that these cells outcompete other cell populations in the ovarian tumor microenvironment, making them a strong target for therapeutic interventions. Full article
(This article belongs to the Special Issue Recent Advances in Nanomedicine-Based Cancer Immunotherapy)
Show Figures

Graphical abstract

Back to TopTop